Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May 1;6(3):695-708.
doi: 10.1177/193229681200600326.

Efficacy of Olibra: a 12-week randomized controlled trial and a review of earlier studies

Candida J Rebello  1 , Corby K Martin, William D Johnson, Carol E O'Neil, Frank L Greenway
Affiliations
Review

Efficacy of Olibra: a 12-week randomized controlled trial and a review of earlier studies

Candida J Rebello et al. J Diabetes Sci Technol. .

Abstract

Background: Intervention strategies that harness the body's appetite and satiety regulating signals provide a means of countering excessive energy intake.

Methods: Eighty-two subjects were enrolled (18-60 years, body mass index: 25-40 kg/m(2)) in a randomized, placebo-controlled, double-blind, parallel trial. During a 12-week period, the effects of Olibra™ fat emulsion (2.1 g twice daily) on food intake, appetite, satiety, weight, and body composition were compared with those of a twice daily administered placebo (1.95 g milk fat). On days -7, 0, and 28, Olibra or the placebo added to 200 g of yogurt was served at breakfast and lunch. Food intake, appetite, and satiety were assessed after lunch and dinner. Body weight was measured on days -7, 0, 14, 28, 56, and 84. Body fat, waist circumference, and waist-hip ratio were determined on days 0 and 84. The Eating Inventory was administered at screening and on day 28. Data relating to 71 subjects were analyzed using analysis of covariance.

Results: At 12 weeks, body weight was reduced in the test group (2.17 ± 0.46 kg standard error of the mean, p < .0001) and the control group (1.68 ± 0.42 kg, p < .0001). Waist circumference decreased by 2.93 ± 0.85 cm in the test group (p = .001) and by 1.78 ± 0.74 cm in the control group (p = .02). Differential weight and waist circumference reductions were not significant. Hunger scores (Eating Inventory) decreased more in the test group (p = .0082). Differential group effects were not significant for body fat, waist-hip ratio, food intake, appetite, and satiety.

Conclusions: At this dose, Olibra did not exert a consistent effect on food intake, appetite regulation, body weight, or body composition.

Trial registration: ClinicalTrials.gov NCT01416051.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject recruitment, randomization, and continuance with the study
Figure 2
Figure 2
Hunger scores on EI collected at screening and prior to food intake test on day 28 (p = .0082). Values are mean ± SEM.
See this image and copyright information in PMC

Comment in

References

    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults. 1999–2008. JAMA. 2010;303(3):235–241. - PubMed
    1. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–1209. - PubMed
    1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. - PMC - PubMed
    1. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008;16(10):2323–2330. - PubMed
    1. Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S37–50. - PMC - PubMed

Publication types

MeSH terms

Associated data